STOCK TITAN

electroCore to Participate at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be presenting at the H.C. Wainwright Global Investment Conference and LD Micro Invitational Conference. 

H.C. Wainwright Global Investment Conference
Date: Tuesday, May 24, 2022 
Time: 7:00 AM EDT
Webcast: H.C. Wainwright Webcast

LD Micro Invitational Conference
Date: Tuesday, June 7, 2022
Time: 10:30 AM PDT
Virtual Viewers: Livestream

Following the conferences, a webcast replay of the presentations will be available on the Investor section of the company’s website, electroCore.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital


ElectroCore Inc

NASDAQ:ECOR

ECOR Rankings

ECOR Latest News

ECOR Stock Data

Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Health Technology, Medical Specialties, Manufacturing, Electromedical and Electrotherapeutic Apparatus Manufacturing
United States

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.